3,925 results match your criteria Breast Cancer[Journal]


Reproductive history and breast cancer survival: a prospective patient cohort study in Japan.

Breast Cancer 2019 Apr 15. Epub 2019 Apr 15.

Department of Breast Surgery, Miyagi Cancer Center Hospital, 47-1 Nodayama, Medeshima-Shiode, Natori, Miyagi, 981-1239, Japan.

Background: Reproductive factors may influence breast cancer progression and patient survival; however, evidence has been limited.

Methods: The associations of reproductive factors with tumor characteristics and patient survival were analyzed among 1468 breast cancer patients diagnosed during 1997-2013 at a single institute in Japan. The patients were followed until 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00972-5DOI Listing

Therapeutic targeting of and mutant breast cancer through mutant p53 reactivation.

NPJ Breast Cancer 2019 15;5:14. Epub 2019 Apr 15.

1Department of Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ USA.

Triple negative breast cancer (TNBC) is an aggressive subset for which effective therapeutic approaches are needed. A significant proportion of TNBC patients harbor either germline or somatic mutations in , or epigenetic silencing of , which renders them deficient in DNA repair. Virtually all deficient breast cancers harbor mutations in suggesting that inactivation of p53 is a requirement for tumor progression in the setting of deficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-019-0110-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465291PMC

Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy.

NPJ Breast Cancer 2019 10;5:13. Epub 2019 Apr 10.

1Department of Radiation Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.

Currently the greatest challenge in oncology is the lack of homogeneity of the lesions where different cell components respond differently to treatment. There is growing consensus that monotherapies are insufficient to eradicate the disease and there is an unmet need for more potent combinatorial treatments. We have previously shown that hypericin photodynamic therapy (HYP-PDT) triggers electron transport chain (ETC) inhibition in cell mitochondria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-019-0108-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458138PMC

Evaluation of a Retroglandular Oncoplastic Technique as a Standard Level I Oncoplastic Breast-Conserving Surgery: A Retrospective Clinicopathologic Study of 102 Patients With Breast Cancer.

Clin Breast Cancer 2019 Feb 20. Epub 2019 Feb 20.

Department of Breast and Sarcoma Surgery, National Institute of Oncology, Budapest, Hungary. Electronic address:

Background: This study presents a novel Level I oncoplastic breast-conserving surgery technique for performing tumorectomy by retroglandular exploration through a skin incision made in the inferior mammary fold.

Patients And Methods: A retrospective single-center cohort study involving patients with early-stage breast cancer (n = 102) was performed. The patient characteristics were recorded, as well as the quality of life rated by BREAST-Q. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.005DOI Listing
February 2019

PIM1 is responsible for IL-6-induced breast cancer cell EMT and stemness via c-myc activation.

Breast Cancer 2019 Apr 15. Epub 2019 Apr 15.

Breast Disease Center, The Affiliated Hospital of Qingdao University, 59 Haier Road, Qingdao, 266000, Shandong, China.

Background: Interleukin-6 (IL-6) has been demonstrated to be a critical factor for breast cancer malignancy. However, the molecular mechanisms by which IL-6 induce breast cancer cells epithelial-mesenchymal-transition (EMT) and stemness remain elusive.

Methods: Breast cancer cell lines T47D and MCF7 were exposed to IL-6, the expression of PIM1 was examined by quantitative real-time PCR (qRT-PCR) and western blot. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00966-3DOI Listing

Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.

Breast Cancer 2019 Apr 12. Epub 2019 Apr 12.

Division of Clinical Genetic Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake Koto-ku, Tokyo, 135-8550, Japan.

Individuals carrying pathogenic BRCA1 or BRCA2 mutations have an increased lifetime risk of breast and/or ovarian cancer. The incidence of breast cancer amongst disease-free BRCA mutation carriers under surveillance and the clinical and pathological characteristics of those who subsequently develop the disease remain unclear in Japan. We reviewed the records of 155 individuals with BRCA1 or BRCA2 mutations identified by genetic testing between January 2000 and December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00971-6DOI Listing

The Loss of Lymph Node Metastases After Neoadjuvant Chemotherapy in Patients With Cytology-proven Axillary Node-positive Primary Breast Cancer.

Clin Breast Cancer 2019 Mar 11. Epub 2019 Mar 11.

Department of Breast Surgical Oncology, St Luke's International Hospital, Tokyo, Japan; Department of Breast Surgical Oncology, Watanabe Hospital, Tokyo, Japan. Electronic address:

Background: Axillary lymph node (LN) dissection after neoadjuvant chemotherapy (NAC) still remains a standard treatment of initially LN-positive primary breast cancer because of the difficulty of assessment of LN status. The aim of this study was to assess the LN status after NAC in initially LN-positive primary breast cancer patients who were assessed as clinically LN-negative after NAC (ycN0) and identify factors associated with loss of LN metastasis.

Patients And Methods: The study cohort comprised 279 patients with cytology-proven LN-positivity before NAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.03.001DOI Listing
March 2019
1 Read

Clinical application of ceramide in cancer treatment.

Breast Cancer 2019 Apr 8. Epub 2019 Apr 8.

Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-ku, Niigata City, Niigata, 951-8510, Japan.

Development of innovative strategies for cancer treatment is a pressing public health issue. Despite recent advances, the mechanisms of cancer progression and the resistance to cancer treatment have not been fully elucidated. Sphingolipids, including ceramide and sphingoshin-1-phosphate, are bioactive mediators that regulate cancer cell death and survival through the dynamic balance of what has been termed the 'sphingolipid rheostat'. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00953-8DOI Listing

NDRG4 promoter hypermethylation is a mechanistic biomarker associated with metastatic progression in breast cancer patients.

NPJ Breast Cancer 2019 5;5:11. Epub 2019 Apr 5.

1Centro de Oncologia Molecular, Hospital Sírio-Libanês, São Paulo, SP Brazil.

The risk of developing metastatic disease in breast cancer patients is traditionally predictable based on the number of positive axillary lymph nodes, complemented with additional clinicopathological factors. However, since lymph node-negative patients have a 20-30% probability of developing metastatic disease, lymph node information alone is insufficient to accurately assess individual risk. Molecular approaches, such as multigene expression panels, analyze a set of cancer-related genes that more accurately predict the early risk of metastasis and the treatment response. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41523-019-0106-x
Publisher Site
http://dx.doi.org/10.1038/s41523-019-0106-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450950PMC
April 2019
2 Reads

Paving the way for changing perceptions in breast surgery: a systematic literature review focused on oncological and aesthetic outcomes of oncoplastic surgery for breast cancer.

Breast Cancer 2019 Apr 6. Epub 2019 Apr 6.

Breast Unit, 1st Department of Obstetrics and Gynecology, Medical School, National and Kapodistrian University of Athens, 11 Pyrgou street, 16675, Glyfada, Athens, Greece.

Background: The emphasis on aesthetic outcomes and quality of life after breast cancer surgery has motivated breast surgeons to develop oncoplastic breast conserving surgery (OPS). Training programs are still rare in most countries, and there is little standardization, which challenges the scientific evaluation of these techniques. This systematic review aims to assess oncological and cosmetic outcomes of OPS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00968-1DOI Listing
April 2019
1 Read

The Global and Regional Survival Rate of Women With Breast Cancer: A Systematic Review and Meta-analysis.

Clin Breast Cancer 2019 Jan 29. Epub 2019 Jan 29.

Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Breast cancer is the most common cancer among women in the world. The aim of this study was to measure the global and regional survival rates of women with breast cancer. We searched Medline/PubMed, Web of Science, Scopus, and Google Scholar to identify cohort studies on the survival rate of women with primary invasive breast cancer until the end of June 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.006DOI Listing
January 2019

Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.

Breast Cancer 2019 Apr 4. Epub 2019 Apr 4.

International University of Health and Welfare Hospital, Nasushiobara, Japan.

Background: This study aimed to identify factors affecting patients' preferences for postmenopausal hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer treatments, their relative importance, and impact of sociodemographic/clinical characteristics.

Methods: Japanese postmenopausal patients with HR+ breast cancer chose between 2 hypothetical treatments for HR+/HER2- advanced breast cancer using an online discrete choice experiment, defined by different levels of 5 attributes: progression-free survival (PFS), incidence of diarrhea (IOD), frequency of loose stools of grade 1-3 severity (FOS), duration of diarrhea (DOD), and route/frequency of administration (RFA). Conditional logit modeling identified relative preferences for each attribute. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00965-4DOI Listing
April 2019
2 Reads

Predicting metastasis in clinically negative axillary lymph nodes with minimum apparent diffusion coefficient value in luminal A-like breast cancer.

Breast Cancer 2019 Apr 1. Epub 2019 Apr 1.

Global Station for Quantum Medical Science and Engineering, Global Institution for Collaborative Research and Education, Hokkaido University, N14, W5, Kita-ku, Sapporo, 060-8648, Japan.

Background: We investigated the usefulness of the minimum ADC value of primary breast lesions for predicting axillary lymph node (LN) status in luminal A-like breast cancers with clinically negative nodes in comparison with the mean ADC.

Methods: Forty-four luminal A-like breast cancers without axillary LN metastasis at preoperative clinical evaluation, surgically resected with sentinel LN biopsy, were retrospectively studied. Mean and minimum ADC values of each lesion were measured and statistically compared between LN positive (n = 12) and LN negative (n = 32) groups. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12282-019-00969-0
Publisher Site
http://dx.doi.org/10.1007/s12282-019-00969-0DOI Listing
April 2019
3 Reads

Detection of human mammaglobin mRNA in breast cancer cells among Vietnamese women.

Breast Cancer (Dove Med Press) 2019 18;11:143-150. Epub 2019 Mar 18.

Department of Oncology, Thanh Nhan Hospital, Hanoi, Vietnam.

Background: Detecting circulating tumor cells (CTCs) is a promising approach for evaluating the progression of occult metastases as well as the efficacy of treatment therapies among patients with breast cancer. A real-time reverse transcriptase polymerase chain reaction (RT-PCR) technique has been proposed for detecting CTCs due to its high sensitivity. In this study, we aimed to validate the RT-PCR technique for human mammaglobin (hMAM) mRNA detection among Vietnamese women with breast cancer. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/detection-of-human-mammaglobin-mrn
Publisher Site
http://dx.doi.org/10.2147/BCTT.S193777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429994PMC
March 2019
1 Read

Nano-curcumin's suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression.

Breast Cancer (Dove Med Press) 2019 13;11:137-142. Epub 2019 Mar 13.

Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran,

Background: Breast cancer is the leading cause of cancer worldwide. The high expenses associated with chemotherapy as well as its side effects make the management of breast cancer a daunting challenge. The most common overexpressed gene in breast cancer is cyclinD1, which induces cell proliferation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BCTT.S195800DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420787PMC

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.

Clin Breast Cancer 2019 Mar 6. Epub 2019 Mar 6.

Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address:

Introduction: GATA3 is a critical transcription factor in maintaining the differentiated state of luminal mammary epithelial cells. We sought to determine the prognostic and predictive roles of GATA3 genotypes for breast cancer.

Patients And Methods: Twelve single nucleotide polymorphisms (SNPs) were genotyped in 2 breast cancer cohorts, including the SWOG S8897 trial where patients were treated with adjuvant chemotherapy (CAF [cyclophosphamide, doxorubicin, 5-fluorouracil] vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.010DOI Listing
March 2019
1 Read

Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy.

Breast Cancer 2019 Mar 29. Epub 2019 Mar 29.

Department of Radiation Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.

Purpose: Recent studies revealed that metabolic stress influences the outcomes of breast cancer treatment. We sought to evaluate the prognostic effect of type 2 diabetes and find the molecular mechanism of relapses in postoperative HER-2+ breast cancer patients treated with HER-2 targeted therapy.

Materials And Methods: We evaluated 190 HER-2+ breast cancer patients (pT1-4N0-2M0) who were treated with surgical resection and trastuzumab (HER-2 targeted therapy) between 2006 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00967-2DOI Listing

Correction to: Breast cancer cell motility is promoted by 14-3-3γ.

Breast Cancer 2019 Mar 29. Epub 2019 Mar 29.

Department of Surgical Oncology, Division of Radiation Biology and Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima, Japan.

The correct name of the corresponding author should be ''Takahiro Mimae'', and not ''Emiko Hiraoka'' as given in the original publication of the article. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00964-5DOI Listing

Characteristics of Patients With Breast Cancer With Brain Metastases Who Live Longer Than 60 Months.

Authors:
Kadri Altundag

Clin Breast Cancer 2019 Mar 6. Epub 2019 Mar 6.

MKA Breast Cancer Clinic, Ankara, Turkey.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.013DOI Listing

Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).

Clin Breast Cancer 2019 Feb 27. Epub 2019 Feb 27.

Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia.

Introduction: The primary objective of this study was to assess the safety and tolerability of combination pertuzumab, subcutaneous trastuzumab (Herceptin), and investigator's choice of taxane chemotherapy in previously untreated patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Efficacy was a secondary objective.

Patients And Methods: This study was an open-label, non-randomized study of patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who had no previous systemic non-hormonal anti-cancer therapy for metastatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.008DOI Listing
February 2019
1 Read

Axillary Lymph Node Tattooing and Targeted Axillary Dissection in Breast Cancer Patients Who Presented as cN+ Before Neoadjuvant Chemotherapy and Became cN0 After Treatment.

Clin Breast Cancer 2019 Feb 6. Epub 2019 Feb 6.

Department of Clinical Oncology, Interbalkan European Medical Center, Thessaloniki, Greece.

Introduction: Targeted axillary dissection (TAD) is an alternative to axillary dissection for breast cancer patients who presented as cN+ before neoadjuvant chemotherapy (NAC) and became cN0 after treatment. TAD is defined as the removal of sentinel lymph nodes (SLNs) along with the pre-NAC marked positive nodes. Tattooing is an option to mark positive nodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.013DOI Listing
February 2019

AKT1 quiescent cancer cells in ductal carcinoma in situ of the breast.

NPJ Breast Cancer 2019 21;5:10. Epub 2019 Mar 21.

5Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114 USA.

Ductal carcinoma in situ (DCIS) of the breast precedes the development of invasive breast cancer and reflects the genomic changes and protein expression profile of invasive disease. AKT1 cancer cells (QCC) are a rare, drug-tolerant, epigenetically plastic, and quiescent cancer cell subset that we previously identified at a frequency of 0.5-1% in primary breast tumors using the marker profile: AKT/H3K9me2/HES1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-019-0105-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428812PMC
March 2019
1 Read

Sentinel node mapping and ductal carcinoma in situ.

Breast Cancer 2019 Mar 22. Epub 2019 Mar 22.

Department of Breast Surgery, Wheeling Hospital, Wheeling, WV, USA.

Background: Pure ductal carcinoma in situ (DCIS) is typically unassociated with a risk of regional lymph node involvement. Retrospective series maintain that larger tumors or high-grade histopathology may harbor a risk of lymph node involvement.

Purpose: Our community hospital retrospectively reviewed a series wherein women with DCIS were subjected to sentinel lymph node biopsy based on large tumor size and/or high-grade histopathology. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12282-019-00960-9
Publisher Site
http://dx.doi.org/10.1007/s12282-019-00960-9DOI Listing
March 2019
16 Reads

Oncologic outcomes and radiation safety of nipple-sparing mastectomy with intraoperative radiotherapy for breast cancer.

Breast Cancer 2019 Mar 19. Epub 2019 Mar 19.

Department of Breast Surgery, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.

Background: Nipple-sparing mastectomy combined with breast reconstruction helps to optimize the contour of the breast after mastectomy. However, the indications for nipple-sparing mastectomy are still controversial. Local radiation to the nipple-areola complex may play some roles in improving the oncological safety of this procedure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00962-7DOI Listing
March 2019
1 Read

Discrepancies of current recommendations in breast cancer follow-up: a systematic review.

Breast Cancer 2019 Mar 18. Epub 2019 Mar 18.

Department of Clinical Therapeutics, General Hospital Alexandra, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.

Introduction: Management and optimal follow-up of early breast cancer survivors remain up to this day a challenge due to the lack of well-established guidelines. Multiple medical societies, organizations and working groups have provided recommendations for follow-up but there is no uniform, globally approved algorithm to guide clinical practice.

Methods: A systematic review was performed to identify and evaluate discrepancies between available guidelines for the follow-up of breast cancer survivors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00963-6DOI Listing

Corrigendum.

Authors:

Breast Cancer (Auckl) 2019 11;13:1178223419834790. Epub 2019 Mar 11.

[This corrects the article DOI: 10.1177/1178223417752677.]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1178223419834790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413418PMC

Targeting stem cells in the realm of drug-resistant breast cancer.

Breast Cancer (Dove Med Press) 2019 7;11:115-135. Epub 2019 Mar 7.

Molecular Functional Imaging Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India,

Since its first documentation, breast cancer (BC) has been a conundrum that ails millions of women every year. This cancer has been well studied by researchers all over the world, which has improved the patient outcome significantly. There are many diagnostic markers to identify the disease, but early detection and then subclassification of this cancer remain dubious. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BCTT.S189224DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410754PMC

A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).

Clin Breast Cancer 2019 Feb 21. Epub 2019 Feb 21.

Gundersen Health System, La Crosse, WI.

Background: Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectomy versus mastectomy in the National Cancer Database (NCDB).

Patients And Methods: A retrospective cohort of patients with stage I-III breast cancer in the NCDB (2004-2013) was identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.006DOI Listing
February 2019

C677T and A1298C methylenetetrahydrofolate reductase polymorphisms and breast cancer susceptibility among Latinos: a meta-analysis.

Breast Cancer 2019 Mar 15. Epub 2019 Mar 15.

Departamento de Genética, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, 13 Sur 2901 Col. Volcanes, C.P. 72420, Puebla, Pue, Mexico.

Background: Previous meta-analyses have shown an ethnic dependency of the C677T and the A1298C methylenetetrahydrofolate reductase (MTHFR) polymorphisms, with no focus on the Latino population. For Latinos, many studies have examined these polymorphisms and breast cancer susceptibility, yielding no concise result. Therefore, we undertook this meta-analysis to determine the effect these polymorphisms have on breast cancer risk for Latinos. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00961-8DOI Listing
March 2019
1.505 Impact Factor

Prophylactic Versus Therapeutic Mastectomy: A Contemporary Analysis of the ACS-NSQIP Database.

Clin Breast Cancer 2019 Jan 31. Epub 2019 Jan 31.

Division of Surgical Oncology, Department of Surgery, University of Massachusetts, Worcester, MA. Electronic address:

Introduction: The objective of the study was to evaluate the morbidity, mortality, and postoperative outcomes associated with simple or subcutaneous mastectomy in the management of prophylactic versus therapeutic resection. In this study we aimed to assess if simple or subcutaneous mastectomy for prophylaxis affects perioperative outcomes compared with resection performed for biopsy proven malignancy.

Materials And Methods: The American College of Surgeons National Surgical Quality Improvement Program database was queried for subjects who underwent simple or subcutaneous mastectomy between 2007 and 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.008DOI Listing
January 2019

Patterns of Care and Efficacy of Chemotherapy and Radiotherapy in Skin-Involved Breast Cancers of All Sizes.

Clin Breast Cancer 2019 Feb 16. Epub 2019 Feb 16.

Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA. Electronic address:

Background: The management of small skin-involved (SI) invasive breast cancers is controversial because although they are considered unresectable, their prognosis is far better than their stage III classification. This study was undertaken to determine how SI lesions are treated in the United States and to discern the benefit of systemic therapy.

Patients And Methods: Data of patients diagnosed with stage I-III breast cancer in the National Cancer Data Base between 2004 and 2011 were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.003DOI Listing
February 2019

Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer.

Breast Cancer 2019 Mar 13. Epub 2019 Mar 13.

Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3-Kasumi, Minami-ku, Hiroshima, Hiroshima, 734-0037, Japan.

Background: The presence of tumor-infiltrating lymphocytes (TILs) is a prognostic factor for breast cancer. However, because of tumor tissue heterogeneity, an accurate and simple evaluation method is needed. We determined if preoperative characteristic ultrasonography (US) image findings are predictive of lymphocyte-predominant breast cancer (LPBC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00958-3DOI Listing
March 2019
2 Reads

Breast cancer risk in a rapidly aging population: advances and approaches to study the aging tissue microenvironment.

Authors:
Steven J Greco

Breast Cancer (Dove Med Press) 2019 19;11:111-113. Epub 2019 Feb 19.

Department of Medicine, Division of Hematology and Oncology, Rutgers-New Jersey Medical School, Newark, NJ, USA,

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385766PMC
http://dx.doi.org/10.2147/BCTT.S200949DOI Listing
February 2019

The antiestrogenic effects of black cohosh on BRCA1 and steroid receptors in breast cancer cells.

Breast Cancer (Dove Med Press) 2019 19;11:99-110. Epub 2019 Feb 19.

Department of Biomedical Diagnostic and Therapeutic Sciences, School of Health Sciences, Oakland University, Rochester, MI 48309-4476, USA,

Background: Black cohosh (BC) is an herbal remedy often used by women to treat symptoms associated with menopause. Research has shown that the molecular activity of BC is associated with estrogen receptor alpha (ER-α) regulation. Progesterone receptor (PR) expression is found to be consistent with ER expression and mutations in the gene, a tumor-suppressor gene, are known to be responsible for about 40%-45% of hereditary breast cancers. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/the-antiestrogenic-effects-of-blac
Publisher Site
http://dx.doi.org/10.2147/BCTT.S181730DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385778PMC
February 2019
10 Reads

Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration.

Breast Cancer (Dove Med Press) 2019 19;11:87-97. Epub 2019 Feb 19.

Breast Center, Department of Gynecology and Obstetrics and CCC Munich, University of Munich (LMU), 81377 Munich, Germany,

Objectives: A correlation exists between breast cancer and thyroid disorders, which are common in elderly women. Thyroid hormones are degraded into trace amines, which can bind to the G-protein-coupled receptor trace amine-associated receptor 1 (TAAR1) and thereby activate it. The transformation of thyroid hormones into trace amines is carried out by the ornithine decarboxylase. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BCTT.S178721DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385785PMC
February 2019
1 Read

Breast cancer prevention in older women: an algorithm to choose an optimal preventive agent.

Breast Cancer (Dove Med Press) 2019 19;11:81-86. Epub 2019 Feb 19.

Department of Geriatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA,

Background: Breast cancer is a significant cause of morbidity and mortality in older women. The current study presents new, comprehensive guidelines for providing chemoprevention to older women.

Objective: The objective of this study was to develop and pilot test a chemopreventive choice algorithm to assess its feasibility for older women at high risk of breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/BCTT.S179486DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385772PMC
February 2019
2 Reads

Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs.

Clin Breast Cancer 2019 Feb 16. Epub 2019 Feb 16.

Department of Oncology, Mater Salutis Hospital, Legnago, Italy.

Purpose: To assess the pharmacologic costs of CDK4/6 inhibitors (palbociclib and ribociclib) in hormone receptor-positive (HR)/human epidermal receptor 2-negative (HER2) advanced or metastatic breast cancer (BC). Pivotal phase 3 randomized controlled trials (RCTs) were considered.

Discussion: Two phase 3 RCTs including 1334 patients were considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.004DOI Listing
February 2019
1 Read

Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.

Clin Breast Cancer 2019 Feb 6. Epub 2019 Feb 6.

Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Ireland. Electronic address:

Background: Two large acute Irish University teaching hospitals changed the manner in which they treated human epidermal growth factor receptor (HER)2-positive breast cancer patients by implementing the administration of trastuzumab via the subcutaneous (SC) route into their clinical practice. The study objective is to compare the trastuzumab SC and trastuzuamb intravenous (IV) treatment pathways in both hospitals and assess which route is more cost-effective and time saving in relation to active health care professional (HCP) time.

Materials And Methods: A prospective observational study in the form of cost minimization analysis constituted the study design. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.011DOI Listing
February 2019
1 Read

Factors Determining Anthracycline Use in Hormone Receptor Positive, Early-Stage Breast Cancer.

Clin Breast Cancer 2019 Feb 7. Epub 2019 Feb 7.

Genesys Research Office, Ascension Genesys, Grand Blanc, MI. Electronic address:

Background: Anthracyclines are associated with significant toxicities whereas nonanthracyclines have proven to be better tolerated. A 21-gene assay allows clinicians to predict who will not benefit from adjuvant chemotherapy and avoid systemic toxicities. Physicians are using the recurrence score to guide chemotherapy selection, despite the lack of evidence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.012DOI Listing
February 2019
1 Read

Intensive Imaging Surveillance of Survivors of Breast Cancer May Increase Risk of Radiation-induced Malignancy.

Clin Breast Cancer 2019 Jan 23. Epub 2019 Jan 23.

Medical Unit, Translational Research In Oncology (TRIO), Montevideo, Uruguay.

Background: Current clinical guidelines recommend mammography as the only imaging method for surveillance in asymptomatic survivors of early breast cancer (EBC). However, non-recommended tests are commonly used. We estimated the imaging radiation-induced malignancies (IRIM) risks in survivors of EBC undergoing different imaging surveillance models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.003DOI Listing
January 2019
1 Read

Lateral thoracoaxillar dermal-fat flap for breast conserving surgery: the changes of the indication and long-term results.

Breast Cancer 2019 Mar 7. Epub 2019 Mar 7.

Department of Plastic Surgery, Yamanashi Prefectural Central Hospital, Fujimi1-1-1, Kofu, Yamanashi, 400-8506, Japan.

Background: Oncoplastic breast conserving surgery had been challenged to achieve both of local control and the cosmetic appearance of preserved breast. We developed the lateral thoracoaxillar dermal-fat flap (LTDF) as an oncoplastic procedure to fill the defect of breast-conserving surgery in 1999.

Methods: A total of 2338 breast cancer patients underwent surgery from January, 2000 to December, 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00959-2DOI Listing

A Genetic Variant of rs145204276 in the Promoter Region of Long Noncoding RNA GAS5 Is Associated With a Reduced Risk of Breast Cancer.

Clin Breast Cancer 2018 Nov 14. Epub 2018 Nov 14.

Department of Breast Surgery, the Third Affiliated Hospital of Kunming Medical University, Kunming Yunnan, P.R. China. Electronic address:

Introduction: Growth arrest-specific 5 (GAS5), downregulated in breast cancer (BC), functions as a tumor suppressor by affecting tumor growth and cell apoptosis in vivo and in vitro. This study was designed to determine whether an insertion (ins)/deletion (del) polymorphism (rs145204276 AGGCA/-) in the promoter region of GAS5 was a susceptibility gene to the occurrence of BC.

Patients And Methods: A hospital-based case-control study was conducted and the GAS5 rs145204276 genotype was analyzed in 575 sporadic BC patients and 602 controls to test the association between the polymorphism and BC risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.11.006DOI Listing
November 2018
2.107 Impact Factor

Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.

Clin Breast Cancer 2019 Feb 7. Epub 2019 Feb 7.

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address:

Background: Fulvestrant 500 mg and exemestane are widely used agents in first-line therapy for metastatic breast cancer (MBC) of estrogen receptor (ER)-positive (ER) postmenopausal MBC after failure of adjuvant nonsteroidal aromatase inhibitor (NSAI) treatment. Although fulvestrant 250 mg had similar efficacy compared with exemestane (Evaluation of Faslodex versus Exemestane Clinical Trial study) and fulvestrant 500 mg was superior to fulvestrant 250 mg (Comparison of FASLODEX In Recurrent or Metastatic Breast Cancer study), no direct comparison between fulvestrant 500 mg and exemestane has been conducted. The aim of this study was to compare the efficacy and safety of fulvestrant 500 mg and exemestane in daily practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.015DOI Listing
February 2019
2 Reads
2.107 Impact Factor

ER/HER2 Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2 Breast Cancer.

Clin Breast Cancer 2019 Feb 14. Epub 2019 Feb 14.

Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA. Electronic address:

Background: Human epidermal growth factor receptor 2-positive (HER2) breast cancer is generally treated with HER2-targeted therapy combined with chemotherapy. Patients with HER2 and estrogen receptor-positive (ER) cancer are additionally treated with long-term hormone therapy. This study examined the metastatic pattern and prognosis of both ER/HER2 and ER-/HER2 breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.02.001DOI Listing
February 2019
2 Reads
2.107 Impact Factor

Screening Mammography Findings in Women With Chronic Kidney Disease on a Renal Transplant Waiting List.

Clin Breast Cancer 2019 Jan 31. Epub 2019 Jan 31.

Department of Radiology, Health Sciences University, Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey.

Background: The incidence of breast cancer has been reported to be increased in people with chronic kidney disease (CKD). Thus, breast cancer screening is stated to be mandatory. However, it is as yet unclear what age group or what type of breast structure indicate a need for mammography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.01.009DOI Listing
January 2019
2 Reads

Bio-Field Array: The Influence of Junction Mediating and Regulatory Protein Expression on Cytoskeletal Filament Behavior During Apoptosis in Triple-Negative Breast Cancer.

Authors:
Marcy C Purnell

Breast Cancer (Auckl) 2019 28;13:1178223419830981. Epub 2019 Feb 28.

The Loewenberg College of Nursing, University of Memphis, Memphis, TN, USA.

Introduction: The Bio-Field Array (BFA) is a device that generates a dielectrophoretic electromagnetic field (DEP-EMF) when placed in a hypotonic saline solution and a direct current (dc) of ~3 amperes is applied. Human triple-negative breast cancer (MDA-MB-231 cells) is known to have a high percentage of apoptotic () deficient cells and some patients can have poor outcomes with current treatments.

Objectives: Previously, we reported a strong upregulation of the apoptotic arm of the unfolded protein response, via reverse transcription-quantitative polymerase chain reaction (RT-qPCR), as well as positive annexin staining in this human breast carcinoma, when grown in media prepared with BFA's dc DEP-EMF treated saline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1178223419830981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396045PMC
February 2019
3 Reads

Vitamin D Receptor in Breast Cancer Tissues and Its Relation to Estrogen Receptor Alpha (ER-α) Gene Expression and Serum 25-hydroxyvitamin D Levels in Egyptian Breast Cancer Patients: A Case-control Study.

Clin Breast Cancer 2019 Jan 6. Epub 2019 Jan 6.

Department of Applied Medical Chemistry, Medical Research Institute, University of Alexandria, Alexandria, Egypt.

Introduction: This study aimed to explore the role of vitamin D receptor (VDR) in breast cancer tissues and its relation to serum 25-hydroxyvitamin D [25(OH)D] levels and estrogen receptor alpha (ER-α) gene expression in patients with breast cancer.

Patients And Methods: Cancerous and normal breast tissues from 40 women with breast cancer were analyzed for quantification of VDR levels and ER-α gene expression. The serum levels of 25(OH)D were measured in patients with breast cancer and controls by radioimmunoassay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.019DOI Listing
January 2019

Breast cancer cell motility is promoted by 14-3-3γ.

Breast Cancer 2019 Mar 4. Epub 2019 Mar 4.

Department of Surgical Oncology, Division of Radiation Biology and Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima, Japan.

Purpose: Pseudopodia are actin-rich ventral protrusions associated with cell motility and cancer cell invasion. We previously applied our established method of using excimer laser cell etching to isolate pseudopodial proteins from MDA-MB-231 breast cancer cells. We later identified 14-3-3γ as an oncogenic molecule among 46 candidate proteins that are specific to pseudopodia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-019-00957-4DOI Listing

Bone Metastasis Prognostic Factors in Breast Cancer.

Breast Cancer (Auckl) 2019 22;13:1178223419830978. Epub 2019 Feb 22.

Information Technology Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.

Objective: Bone is the most common site of metastasis in breast cancer. Prognostic factors for predicting bone metastases in breast cancer are controversial yet. In this study, we investigated clinical factors associated with secondary bone metastasis of breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1178223419830978DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388452PMC
February 2019
1 Read

Obesity Does Not Influence Management of Advanced Breast Cancer in the Elderly.

Clin Breast Cancer 2019 Jan 12. Epub 2019 Jan 12.

Division of Surgical Oncology, Department of Surgery, Rush University Medical Center, Chicago, IL.

Background: Obesity is becoming increasingly common in the elderly population, and it adds to the complexity of treatment decisions in this population. We aimed to investigate whether body mass index (BMI) affects care in this subset of patients.

Patients And Methods: We performed a retrospective chart review on 118 patients over the age of 70 years diagnosed with breast cancer and pathologically proven axillary disease over an 8-year period at an urban academic hospital and compared BMI to treatment received, clinical stage, and hormone receptor status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.12.020DOI Listing
January 2019